At a time of the emergence of drug-resistant bacterial strains, the development of antimicrobial compounds with novel mechanisms of action is of considerable interest. Perhaps the most promising among these is a family of antibacterial peptides originally isolated from insects. These were shown to act in a stereospecific manner on an as-yet unidentified target bacterial protein. One of these peptides, drosocin, is inactive in vivo due to the rapid decomposition in mammalian sera. However, another family member, pyrrhocoricin, is significantly more stable, has increased in vitro efficacy against Gram-negative bacterial strains, and if administered alone, as we show here, is devoid of in vitro or in vivo toxicity. At low doses, pyrrhocoricin protected mice against Escherichia coli infection, but at a higher dose augmented the infection of compromised animals. Analogs of pyrrhocoricin were, therefore, synthesized to further improve protease resistance and reduce toxicity. A linear derivative containing unnatural amino acids at both termini showed high potency and lack of toxicity in vivo and an expanded cyclic analog displayed broad activity spectrum in vitro. The bioactive conformation of native pyrrhocoricin was determined by nuclear magnetic resonance spectroscopy, and similar to drosocin, reverse turns were identified as pharmacologically important elements at the termini, bridged by an extended peptide domain. Knowledge of the primary and secondary structural requirements for in vivo activity of these peptides allows the design of novel antibacterial drug leads.
completely degraded in diluted human and mouse sera within a 4-h period~Hoffmann et al., 1999!. Both aminopeptidase and carboxypeptidase cleavage pathways are observed. Pyrrhocoricin appears to be more resistant to degradation in mouse serum than drosocin, but decomposes relatively quickly in some batches of human se-rum~Hoffmann et al., 1999!. The first metabolites from serum stability assays were identified, and it was shown that the metabolites of drosocin and pyrrhocoricin, lacking as few as five amino terminal or two carboxy terminal amino acids become inactive in vitro~Bulet et al., 1996; Hoffmann et al., 1999 !. Although experiments measuring the rate of peptide degradation are fairly straightforward, there are several serum batch-related factors that may produce highly variable results~Powell et al., 1993!. The use of pooled human sera somewhat improves the reproducibility of the stability assays, although even commercial sera with the same catalog number are notoriously different. Therefore, in the current study, we investigated the stability of the pyrrhocoricin-related peptides in two different batches of pooled human serum~approximately 80 donors in each batch!.
The hypothesis concerning the two independent active sites is further supported by a recent model of the bioactive secondary structure of drosocin that identifies two reverse turns, one at each terminal region, as binding sites to the target molecule~McManus et al., 1999!. The situation is further complicated by the fact that the degradation speed and pathway of a given peptide in diluted mouse serum is somewhat different from those observed in diluted human serum. The stability of the peptides is markedly increased in insect hemolymph where they manifest their biological functioñ Hoffmann et al., 1999!. We decided to design modified peptides based on pyrrhocoricin. Our goal was to retain the peptide's high antibacterial potency in vitro and obtain good metabolic stability and lack of toxicity for ensuing in vivo efficacy assays and drug development. We selected pyrrhocoricin over drosocin because~1! it is more potent against some strains of Gram-negative bacteria,~2! glycosylation is not needed for full biological activity, and~3! the peptide is more stable in mouse serum. Importantly, we wanted to obtain peptides for which the degradation pathway in mouse serum~the most suitable test animal for in vivo efficacy assay! is similar to that in human serum~the modified peptides are targeted for human therapy!. In addition, we wanted to determine the bioactive conformation of native pyrrhocoricin and compare it with that of the published structure of native drosocin to establish the secondary structural requirements for antibacterial activity.
Results and discussion

Design of peptides
Pyrrhocoricin has the amino acid sequence: VDKGSYLPRPTP-PRPIYNRN, with Thr11 glycosylated in the native peptide. In our earlier studies, we synthesized the peptide with a free aminoterminus and an amidated carboxy-terminus. In the current study, an extensive series of fragments and analogs was made for biochemical characterization of the peptide and for drug design purposes. The following findings were considered in the design of pyrrhocoricin analogs for biotechnological uses:~1! the main sites of the degradation of unmodified pyrrhocoricin are the N-and the C-termini, indicating mainly exopeptidase cleavage;~2! an endopeptidase cleavage site was also identified between Ser6 and Tyr7; 3! N-terminal acetylation usually protects peptides from amino-peptidase cleavage;~4! however, most antibacterial peptides need a positive charge at or near the native amino terminus~Vunnam et al., 1997!;~5! unnatural, glycosylated, or d-amino acid residues are likely candidates to improve stability in serum~Powell et al., 1993!; and~6! cyclic peptides cannot be cleaved by exopeptidases. In this first round of studies, we did not consider backbone modifications to conserve the conformation of the peptide. As backbonemodified versions of a membrane-active antibacterial peptide were reported to improve proteolytic stability and yield analogs with slightly modified activity spectrum~Oh et al., 1999!, backbone modifications will be considered in future steps. Table 1 lists the synthetic peptides and the in vitro antibacterial activities.
In vitro antibacterial activity
The in vitro antibacterial activity of the peptides was measured against two Gram-positive strains, Micrococcus luteus and Bacillus megaterium, and three Gram-negative strains, E. coli D22, Agrobacterium tumefaciens, and Salmonella typhimurium. Although these bacterial strains are not necessarily clinically relevant, we used these models to obtain a direct comparison with the antimicrobial activity of other related peptides, most importantly drosocin and its fragments~Hoffmann et al., 1999!. The experiments were conducted over a seven-month period. To assess the variability of the assay, peptide 18 was reassayed three months after the original study. The differences in the IC 50 values between 180a and 180b demonstrate this variability. Basically identical results were obtained against M. luteus, B. megaterium, E. coli D22, and S. typhimurium, indicating the high reproducibility of the assay. The fourfold difference in the IC 50 value against A. tumefaciens is in line with the culture-to-culture variability of this strain. From the peptides made for biochemistry investigations, we learned that the two putative binding sites cannot be separated~peptides 2 and 3!. In fact, an equimolar mixture of shorter peptides 2 and 3 remained inactive in all five bacterial strains studied. An analog made of only D-amino acids was similarly inactive~peptide 4!, indicating that pyrrhocoricin, like drosocin, binds stereospecifically to a target protein. The N-terminus of the native glycopeptidẽ peptide 5! could not be blocked by acetylation without a major loss of antibacterial activity. Pyrrhocoricin analogs containing labels and an additional lysine at the N-terminus~peptides 6 and 7! retain biological activity and can later be used to isolate and characterize the bacterial target protein.
Turning to the drug candidates, modification at either termini reduced the potency of unmodified pyrrhocoricin. From the only N-or C-terminally modified peptides, 1-amino-cyclohexylcarboxylic acid at the amino-~peptide 11! and the acetylated 2,3diamino-propionic acid at the carboxy-terminus~peptide 12! appeared to retain most of pyrrhocoricin's antibacterial activity. For drug development, both termini have to be modified to block or at least slow down exopeptidase cleavage that was observed on the native and unglycosylated peptides. Peptides containing modifications at both termini featured acetylation together with positively charged amino acid addition, incorporation of unnatural amino acids, such as Chex or Dap~Ac!, glycosylation, imide formation, and D-amino acid substitution or cyclization~peptides 13-23!. Considering the requirement for submicromolar activity against at least one strain, peptide 19, Chex-pyrrhocoricin-Dap~Ac!, and peptide 18, Ac-R-pyrrhocoricin-Dap~Ac!, were selected for further studies, which included cell toxicity and serum stability as well as metabolism assays. These peptides showed remarkable high activ-
In vivo active antibacterial peptides ity against Gram-negative bacteria. Significantly, the best analog for killing both Gram-negative and Gram-positive bacteria was cyclic peptide cyclo-@K-pyrrhocoricin 1-20-14-7#~peptide 23!, which demonstrated a broad activity spectrum at low micromolar concentrations. In this peptide, a lysine residue was added to the amino terminus of the peptide, which is cyclized with an eightresidue spacer between the original N-and C-termini. The spacer corresponded to the middle domain of pyrrhocoricin and was incorporated backward to remain in register with the original copy of this fragment. This arrangement retained the native orientation of the bioactive domains~the original termini!. The synthesis of this peptide in quantities large enough for toxicity and in vivo efficacy studies, as well as detailed conformational analysis, is currently in progress in our laboratory.
Cytotoxicity of pyrrhocoricin and its analogs
To test whether native and modified pyrrhocoricin peptides were toxic to mammalian cells, pyrrhocoricin, Chex-pyrrhocoricin-Dap~Ac!, Ac-R-pyrrhocoricin-Dap~Ac!, melittin~positive control!, and peptide 31D, a T-cell epitope~negative control! were mixed with sheep erythrocytes. At a final concentration of 40 mM, only melittin lysed the red blood cells~Table 2!. When the experiments were repeated with pyrrhocoricin and the Chex-pyrrhocoricin-Dap~Ac! peptide up to 256 mM concentration, the peptides remained completely nontoxic to sheep erythrocytes. In another toxicity assay, COS cell survival was studied upon addition of pyrrhocoricin. Cell counts and rate of proliferation remained unchanged after addition of peptide up to 50 mg0mL concentration. Analogs for biochemistry studies 2 Pyrrhocoricin 1-9 -----3
Pyrrhocoricin 10-20
Biotin-K-pyrrhocoricin 1-20 5 -Ͻ0.15 1.25 1.25 7
Fluorescein-K-pyrrhocoricin 1-20 80 -5 20 40
N-terminal modifications 8 Ac-K-pyrrhocoricin 1-20 40 -0.6 5 40 9
Ac-K-VDK-pyrrhocoricin 1-20 80 -0.3 10 5 10
Ac-R-pyrrhocoricin 1-20 5 -0.6 2.5 2.5 11
Chex-pyrrhocoricin 2-20 5 10 0.3 1.25 2.5
Dual modifications 13 Ac-K-pyrrhocoricin 1-19-D20 --2.5 40 -14
Ac-K-pyrrhocoricin 1-20 imide~N20! 5 20 0.3 1.25 2.5 15
Ac-K-pyrrhocoricin 1-20 GlcNAc~N20! 40 -0.6 5 2.5 16
Ac-K-pyrrhocoricin 1-20 Ac 3 GlcNAc~N20! 40 40 0.6 2.5 20 17
Ac
Chex-pyrrhocoricin 2-19-Dap~Ac! 10 40 0.6 5 2.5 20 d-val-pyrrhocoricin 2-19-D-asn 10 -0.6 2.5 5
External and internal modification 21
Cyclo-@K-pyrrhocoricin 1-20-14-7# 0.6 2.5 0.6 2.5 5 a Abbreviations: V, valine; D, aspartic acid; K, lysine; G, glycine; S, serine; Y, tyrosine; L, leucine; P, proline; R, arginine; T, threonine; I, isoleucine; N, asparagine; A, alanine, F, phenylalanine; Ac, acetyl; Chex, 1-amino-cyclohexane-carboxylic acid; Dap~Ac!, b-acetyl-2,3-diamino propionic acid; GlcNAc, 2-acetamido-2-deoxy-glucose; GalNAc, 2-acetamido-2-deoxy-galactose; Gal, galactose; D-val, D-valine; D-asn, D-asparagine; fluorescein, 5~6!carboxy-fluorescein.
The inhibitory concentration~IC 50 ! is expressed as the concentration tested at which 50% growth inhibition is observed. Growth inhibition assays were performed at 30 8C for 24 h in Luria-Bertani rich nutrient medium. No activity up to 80 mM concentration is indicated by -. Peptide 22 was tested up to 20 mM concentration.
All amino acids were of the L-configuration, except for peptides 4 and 20, in which the indicated amino acids were of the D-configuration. All carbohydrates were of the D-configuration.
Peptide stability in mammalian serum
In vivo stability of peptides in blood is currently modeled well by in vitro stability in serum or plasma~neglecting renal and hepatic clearance!~Powell et al., 1993!. Serum stability studies represent one of the most important secondary screening assays in peptide drug development, largely because they eliminate peptides that have short half-lives and are, therefore, unlikely to be therapeutically effective~Powell et al., 1993!. Because diluted serum increases peptide recovery as well as retards the reaction kinetics to a manageable rate, the experiments were performed using 25% aqueous sera. It has been demonstrated earlier that the degradation rates are linearly proportional to serum concentration~Powell et al., 1992!. We used mouse serum and two different batches of pooled human sera. In our experience, reproducible results can be obtained by using a given serum preparation over a long time period, but batch-to-batch variations result in highly variable decomposition curves. The mouse serum was identical to the one that was used to characterize the metabolic behavior of drosocin~Hoffmann et al., 1999!. When evaluating the first metabolites after 45 min digestion~Table 3!, it was evident that the C-terminal asparagine is cleaved off the unmodified pyrrhocoricin~peptide 1!. In contrast, the modified C-terminal residue stayed on the peptides containing a carboxy-terminal Dap~Ac! residue that replaced Asn20 peptides 18 and 19!. The Ac-R-N-terminal peptide~peptide 18! produced more internal cleavage products close to the amino terminus than the Chex-N-terminal peptide~peptide 19!, most notably a fragment in which the VDK tripeptide fragment was missing. While for unmodified pyrrhocoricin~peptide 1! the degradation products were different in the two human sera, for the Chexpyrrhocoricin-Dap~Ac! peptide~peptide 19! they were very similar. They were also closer to those observed after digestion with the a The missing residues are indicated~e.g., -C2 means that the C-terminal two residues were cleaved off !. For Ac-R-pyrrhocoricin-Dap~Ac!~peptide 18!, the N-terminal residue numbers correspond to unmodified pyrrhocoricin. The relative amounts of the degradation products are estimated based on the MALDI-MS peak heights. 0 ϭ not detected; 1 ϭ very weak~below 5,000!, 2 ϭ weak 5-10,000!, 3 ϭ medium~10-15,000!, 4 ϭ strong~15,000-uncleaved molecular ion at 25-30,000!, 5 ϭ very strong~above uncleaved molecular ion!. All identified degradation products are listed.
The mouse and the human 1 serum are approximately one year old, kept frozen. The human 2 serum is a month old~identical SIGMA catalog number as human 1!. mouse serum. Mice being the species for ensuing in vivo efficacy studies, mouse serum appeared to be a good model for the study of the in vivo efficacy of peptide 19. Figure 1 shows the kinetics of the degradation for peptides 1 and 19. The degradation curves for unmodified pyrrhocoricin~peptide 1! and the Chex-pyrrhocoricin-Dap~Ac! peptide~peptide 19! were similar. Unmodified pyrrhocoricin was somewhat more stable than peptide 19 in mouse serum and in the weaker human serum, but less stable in the more active human serum. Although the lack of exopeptidase cleavage sites reduced the degradation rate of peptide 19 compared to peptide 1, this loss of protease activity was compensated for by increased endopeptidase activity C-terminal to Ser5 and Asn18. In support of this, metabolism studies of the broad spectrum cyclo-@K-pyrrhocoricin 1-20-14-7# derivative~peptide 23! indicated a single endopeptidase cleavage site between Asn18 and Arg19 in both mouse and human sera. In accordance with the increased number and amount of internal degradation products near the amino termini, the Ac-R-pyrrhocoricin-Dap~Ac! peptide~peptide 18! degraded considerably faster than either peptide 1 or peptide 19~data not shown!. Remarkably, after 8 h of digestion, in mouse serum, where the in vivo experiments were planned, both peptides 1 and 19 had 20% of the initial amounts intact. Because we currently use the peptides well above the efficacious concentrations, this 20% remaining uncleaved peptide amount can successfully protect the experimental animals from live bacterial challenge.
In vivo antibacterial activity
Peptides 1 and 19 were submitted to in vivo toxicity and antibacterial efficacy assays~Fig. 2!. Mice of the CD-1 strain were intravenously infected with E. coli strain ATCC 25922. Peptides were intravenously injected 1 h after infection at 10, 25, and 50 mg0kg doses, followed by a second injection after 5 h. The survival rate was compared with that of control mice who were submitted to the same peptide treatment, but received 5% dextrose~DS5! in-stead of the bacteria. Neither peptide alone showed any toxicity at the 50 mg0kg dose. To assess the success of the infection, five mice were infected with E. coli, but received DS5 instead of the test peptides. Of these control mice, two died on the third day and the other three became clinically ill, which included decreased activity and head tilt. When the efficacy of the peptides was studied, the Chex-pyrrhocoricin-Dap~Ac! derivative~peptide 19! protected all 15 mice, regardless of the dose. For unmodified pyrrhocoricin~peptide 1!, the mice that were injected with 10 and 25 mg0kg survived without any clinical signs of disease. However, from the 50 mg0kg group, one mouse died and the other four showed clinical signs of disease. This mirrors the drosocin studies in which the peptide was not toxic alone, but became toxic~or augmented the infection! when the mice were infected and became compromised~Hoffmann et al., 1999!. Increased mortality is an often detected pharmacological phenomenon when high doses of drugs are administered to challenged animals. Such an effect was not found for the Chex-pyrrhocoricin-Dap~Ac! peptide. All mice showed some enlargement of the abdominal region during the study; therefore, at termination, the mice were necropsied. Stomachs and intestines were observed to be enlarged due to the presence of food or stool. There were no other findings. These data indicate that the increase of the proteolytic stability of the pyrrhocoricin peptides compared to drosocin resulted in peptides capable of protecting mice against bacterial infection. The results also warrant further pharmaceutical development with peptides based on the Chex-pyrrhocoricin-Dap~Ac! lead. This analog showed good potency, complete lack of toxicity, and similarity in the degradation pathway between human and mouse sera. The 10-50 mg0kg dosage range was applied to obtain direct comparison with the drosocin study~Hoffmann et al., 1999!. Our next experiments will include the identification of the lowest active dose, optimal mode of delivery, and determination of in vivo activity spectrum of peptide 19 and peptide 23.
Conformation of native pyrrhocoricin
Because native pyrrhocoricin could not be shortened nor could the amino acid composition be changed without a loss of in vitro antibacterial activity, we hypothesized that the peptide has to assume a certain secondary structure to bind stereospecifically to the target protein. Accordingly, we determined the bioactive conformation of native glycosylated pyrrhocoricin and its nonglycosylated analog~peptide 1! by two-dimensional nuclear magnetic resonance~NMR! spectroscopy. Here, the structures are described in comparison with the recently published conformation of droso-cin~McManus et al., 1999!. It appeared that the structure of pyrrhocoricin, like drosocin, was largely random coil, and there was little change in the backbone conformation upon glycosylation. For pyrrhocoricin, however, there was a subpopulation with organized structure at both the N-and C-termini. Figure 3A and 3B summarize the short-and medium-range nuclear Overhauser effects~NOEs! and show that there were a series of d NN~i, iϩ1! NOEs present at both the N-and C-termini of the pyrrhocoricins. Additional d aN~i, iϩ2! NOEs were found in the spectra of the glycosylated derivative. Taken together, these data indicated the presence of reverse turns at the pharmacologically important terminal regions. The increase in the turn potential at the termini compared to drosocin~McManus et al., 1999! may explain the increased in vitro antibacterial activity of pyrrhocoricin~Hoffmann et al., 1999!. A comparison of the aH NMR shifts with random coil values~Merutka et al., 1995! Fig. 1 . Stability of pyrrhocoricin~peptide 1!~open symbols! and Chexpyrrhocoricin-Dap~Ac!~peptide 19!~closed symbols! in 25% aqueous mammalian sera. The peptides were incubated in serum on the same day in triplicate, and the resulting samples were chromatographed over a twoweek period. The incubation temperature was 37 8C. Squares correspond to digestion in mouse serum, and triangles correspond to digestion in human sera. The experimental data were collected in triplicate and were fitted to an exponential equation by the SlideWrite program for graphical representation. is shown in Figure 3C . These results suggested that the middle domain of pyrrhocoricin, like drosocin, had an extended structure. Both the unordered-turn conformational equilibrium and the presence of extended regions were further verified by circular dichro-ism~CD! spectroscopy~data not shown!. Nonglycosylated pyrrhocoricin~peptide 1! exhibited a linear unordered r reverse turn conformational transition upon going from water to trifluoroethanol as solvents. The CD spectrum of the native glycopeptide Fig. 2 . In vivo antibacterial activity of pyrrhocoricin~peptide 1!~open symbols! and Chex-pyrrhocoricin-Dap~Ac!~peptide 19!~closed symbols!. Three mice per group were used for toxicity~broken lines!, and five mice per group were used for efficacy studies~solid lines!. Five additional mice were infected with E. coli ATCC 25922 for negative controls and received 5% dextrose~DS5! instead of test peptides~dots and dashes with crosses!.
A B C Fig. 3 . Summary of NOE connectivities~A and B! and deviations of the aH chemical shifts from their "random coil" values~C! for nonglycosylated pyrrhocoricin~peptide 1!, and its native counterpart, containing a Gal-GalNAc disaccharide moiety on Thr11. The random coil values~Merutka et al., 1995! are corrected for sequence-specific shift of 0.29 ppm for residues preceding Pro. For the NOE connectivities, the intensities are indicated by the thickness of the line. recorded in water was more similar to those of unordered peptides type U spectra!. However, the type C spectrum, and therefore the final turn structure, was stabilized at a lower trifluoroethanol con-centration~50%! for the glycopeptide compared to the nonglycosylated analog, fully supporting the NMR findings. The broadening of the negative band between 210 and 220 nm in the aqueous spectra identified the presence of extended structures for both peptides.
In summary, according to the NMR data, the bioactive conformation of native pyrrhocoricin involves two reverse turns at the termini bridged by an extended peptide segment in the middle domain. This hypothetical structure is supported by the antibacterial activity of the cyclic peptide analogs. Cyclization stabilizes reverse turns~Woody, 1985! and was expected to improve potency, but the cyclic pyrrhocoricin derivative, without expanding the cy-cle~peptide 22!, lost activity compared to the analog linear peptidẽ peptide 13!, probably due to distortion of the extended domain in the middle of the peptide. When the ring size was increased by repeating an internal octapeptide fragment~peptide 23!, the resulting cyclic analog became highly active against both Gram-negative and Gram-positive bacterial strains. This hypothesis will be tested experimentally when higher amounts of the cyclo-@K-pyrrhocoricin 1-20-14-7# peptide are available for detailed CD and NMR studies. High resolution conformational analysis of the drug lead Chexpyrrhocoricin-Dap~Ac! peptide~peptide 19! is also currently in progress in our laboratories. This structure will be reported later, together with the complete pharmacological profile of this peptide analog.
Materials and methods
Peptide synthesis
Peptides were assembled by a Milligen 9050 continuous-flow automated synthesizer on a Fmoc-PAL-polyethylene-glycolpolystyrene copolymer resin with an initial load of 0.17 mmol0g PerSeptive Biosystems, Warrington, United Kingdom!. Standard Fmoc-chemistry was used throughout~Fields & Noble, 1990! with 4 mol excess of the acylating amino acids and HATU~1-hydroxy-7-azabenzotriazole uranium salt! activation, recommended for the synthesis of complex peptides~Angell et al., 1994!. The side-chain protecting groups were trityl for Asn, tert-butyl ether for Tyr, Ser, and Thr, tert-butyl ester for Asp, 2,2,5,7,8-pentamethyl-chroman-6-sulfonyl for Arg, and tert-butyloxy-carbonyl for Lys. Fmoc-1amino-cyclohexane-carboxylic acid was purchased from Neosystem Laboratoire~Strasbourg, France!. Fmoc-diamino-propionic acid from Bachem Biosciences~King of Prussia, Pennsylvania! was acetylated with equimolar amount of pentafluorophenyl acetate prior to peptide synthesis and was used for peptide assembly without any further purification. The glycopeptides were synthesized from commercially available glycoamino acid building blocks, including Fmoc-Thr@Gal~Ac 4 !-GalNAc~Ac 2 !#-OH and Fmoc-Asn@GlcNAc~Ac 3 !#-OH~Novabiochem, San Diego, California!. Peptides were cleaved from the solid support by trifluoroacetic acid in the presence of m-cresol~2.5%!, ethane-dithiol~2.5%!, thioanisole~5%!, and water~5%! as scavengers for 2-3 h. Deacetylation of the sugar hydroxyl groups was accomplished by a 2 min treatment with 0.1 M NaOH~Otvos et al., 1994!. After cleavage, peptides were purified by reversed-phase high-performance liquid chromatography. The final products were characterized by matrixassisted laser desorption0ionization mass spectrometry at the Wistar Institute Protein Microchemistry Laboratory on a Voyager Biospectrometry Workstation by standard methods. Mass spectra verified the anticipated composition of the peptides.
In vitro antibacterial and hemolytic assays
Antibacterial assays were performed in sterile 96-well plates~Nunc F96 microtiter plates! with a final volume of 100 mL as described earlier~Bulet et al., 1996!. Briefly, 90 mL of a suspension of a midlogarithmic phase bacterial culture at an initial 600 nm ultra-violet~UV! absorbance of 0.001 in Luria-Bertani-rich nutrient medium was added to 10 mL of serially diluted peptides in sterilized water. The final peptide concentrations ranged between 0.15 and 80 mM. Plates were incubated at 30 8C for 24 h with gentle shaking, and growth inhibition was measured by recording the increase of the UV absorbance at 600 nm on a SLT Labinstruments 400 ATC microplate reader. The higher temperature compared to traditional antibacterial assays~25 8C! was applied to increase the sensitivity of the assay. Hemolytic activity was assayed with sheep erythrocytes suspended in Alsever's solution~BioWhittaker, Walkersville, Maryland!, and diluted with Dulbecco's phosphate-buffered saline, pH 7.2. Thirty microliters of 1% suspension of the red blood cells was incubated with agitation at 39 8C with 30 mL of 40-256 mM peptides dissolved in phosphate-buffered saline for 1 h and centrifuged at 1,000 g for 5 min. Fifty microliters of the supernatant was collected, and the release of hemoglobin was detected by measuring the UV absorbance at 405 nm.
In vivo toxicity and efficacy studies
In vivo toxicity and antibacterial activity of pyrrhocoricin and the Chex-pyrrhocoricin-Dap~Ac! derivative were evaluated at Chrysalis Preclinical Services Corporation~Olyphant, Pennsylvania!. The conditions were designed to duplicate those during the similar assay of drosocin~Hoffmann et al., 1999!. According to this protocol, male mice of CD-1 strain~Harlan Sprague Dawley, Inc., Stamford, Connecticut! were intravenously infected in the tail with 1,000,000 colony forming units~0.2 mL! of E. coli strain ATCC 25922. To obtain better infection, mice were also fed with E. coli. With this infection strategy, one of five control mice died on day 1, and two of five mice died on day 2. All the control mice remaining alive became clinically sick by day 2. The pyrrhocoricin peptides were intravenously injected 1 h after infection at doses of 10, 25, and 50 mg0kg, followed by a booster injection of the peptides after 5 h of infection. Mice were observed at 1 and 5 h, 1 and 2 days postinfection for clinical signs or mortality, and were compared with control mice who received 5% dextrose~DS5! instead of peptides~negative controls!, or were submitted to the same peptide treatment, but received 50 mg0kg of DS5 instead of the bacteria~toxicity!. Clinical signs included decreased activity and head tilt.
NMR spectroscopy
1 H NMR spectra were recorded on a Bruker DMX 750 MHz spectrometer at temperatures in the range 283-298 K. The sample consisted of 600 mg of native glycosylated or nonglycosylated pyrrhocoricin in 125 mL of 50% TFE-d 3 :50% H 2 O solution in a 2.5 mm NMR tube. Two-dimensional total correlation spectros-copy~TOCSY! and NOE spectroscopy~NOESY! spectra were recorded in the phase-sensitive mode using time-proportional phase incrementation for quadrature detection in the f1-dimension~Marion & Wüthrich, 1983!. TOCSY spectra were recorded using an MLEV-17 mixing scheme~Bax & Davis, 1985! with mixing times of 80 ms, 16 scans, and 512 increments. NOESY spectra were recorded with mixing times of 100 and 300 ms, 64 scans, and 512 increments. All two-dimensional spectra were collected over 4,096 data points in the f2 dimension, with a spectral width of 9,800 Hz in both dimensions. The water proton signal was suppressed using the WATERGATE method~Piotto et al., 1992!, consisting of two sine-shaped gradient pulses on either side of a binomial 3-9-19 pulse of 10 kHz field strength. Spectra were referenced to DSS. The data were processed on a Silicon Graphics~SGI 4D030! computer using the UXNMR software package. The f1-dimension was zero-filled to 4,096 real data points, with f1-and f2-dimensions being multiplied by a squared sine function and Gaussian function, respectively, prior to Fourier transformation.
